摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-哌嗪乙酸 | 14566-74-6

中文名称
2-哌嗪乙酸
中文别名
——
英文名称
2-piperazinylacetic acid
英文别名
2-piperazin-1-ium-2-ylacetate
2-哌嗪乙酸化学式
CAS
14566-74-6
化学式
C6H12N2O2
mdl
MFCD08235224
分子量
144.173
InChiKey
VGEOCVZKPBSYQC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    329.1±17.0 °C(Predicted)
  • 密度:
    1.102±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -3.6
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.833
  • 拓扑面积:
    61.4
  • 氢给体数:
    3
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933599090

SDS

SDS:7008b7b59f38eca9defbe17abac78e61
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] ENANTIOPURE HETEROCYCLIC COMPOUND USEFUL FOR THE PREPARATION OF PEPTIDES WHICH CAN BE POTENTIALLY USED AS MEDICAMENTS
    [FR] COMPOSE HETEROCYCLIQUE ENANTIOPURE UTILISE DANS LA PREPARATION DE PEPTIDES SUSCEPTIBLES DE SERVIR DE MEDICAMENTS
    摘要:
    手性纯的杂环化合物,其化学式为(I),其中J选自C、N、O和S;Z为H或用于保护氨基官能团的基团,R3表示H或有机残基,m为0、1或2,n为0、1或2,杂环最好与至少一个CH2-COOR3之外的取代基取代。
    公开号:
    WO2006037775A1
  • 作为产物:
    描述:
    2-(1,4-Dibenzylpiperazin-2-yl)acetic acid 在 palladium on activated charcoal 盐酸氢气 作用下, 以 甲醇 为溶剂, 生成 2-哌嗪乙酸
    参考文献:
    名称:
    [EN] ENANTIOPURE HETEROCYCLIC COMPOUND USEFUL FOR THE PREPARATION OF PEPTIDES WHICH CAN BE POTENTIALLY USED AS MEDICAMENTS
    [FR] COMPOSE HETEROCYCLIQUE ENANTIOPURE UTILISE DANS LA PREPARATION DE PEPTIDES SUSCEPTIBLES DE SERVIR DE MEDICAMENTS
    摘要:
    手性纯的杂环化合物,其化学式为(I),其中J选自C、N、O和S;Z为H或用于保护氨基官能团的基团,R3表示H或有机残基,m为0、1或2,n为0、1或2,杂环最好与至少一个CH2-COOR3之外的取代基取代。
    公开号:
    WO2006037775A1
点击查看最新优质反应信息

文献信息

  • [EN] MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS POUR LE RÉCEPTEUR MAS COUPLÉ À LA PROTÉINE G ET TRAITEMENT DES TROUBLES QUI Y SONT APPARENTÉS
    申请人:ARENA PHARM INC
    公开号:WO2013070657A1
    公开(公告)日:2013-05-16
    The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.
    本发明涉及式(I)化合物及其药用可接受的盐、溶剂和水合物,这些化合物在治疗和缓解由缺血引起的心脏、脑、肾脏、免疫系统和生殖系统的疾病和紊乱方面具有用处,或者在缺血后再灌注引起的疾病和障碍,以及与之相关的任何下游并发症。本发明还涉及治疗和缓解由血管收缩或高血压引起的血管疾病和障碍的方法,以及由高血压和/或组织灌注减少引起的任何下游并发症。
  • Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
    申请人:3-Dimensional Pharmaceuticals, Inc.
    公开号:US20030105111A1
    公开(公告)日:2003-06-05
    The present invention is directed to a compound of Formula I: 1 wherein A, R 1 , and R 2 are defined herein. The present invention is also directed to compositions comprising compounds of Formula I, methods of using compounds of Formula I, and methods of making compounds of Formula I.
    本发明涉及一种具有以下结构的化合物:其中A、R1和R2在此处被定义。本发明还涉及包含Formula I化合物的组合物、使用Formula I化合物的方法以及制备Formula I化合物的方法。
  • N-heterocyclic derivatives as NOS inhibitors
    申请人:Berlex Laboratories, Inc.
    公开号:US20020183323A1
    公开(公告)日:2002-12-05
    N-Heterocyclic derivatives of the formula (I): 1 are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.
    本文描述了公式(I)中的N-杂环衍生物1,以及其他N-杂环,作为一氧化氮合酶的抑制剂。本文还描述了含有这些化合物的制药组合物,使用这些化合物作为一氧化氮合酶抑制剂的方法,以及合成这些化合物的过程。
  • Pyrazole derivative
    申请人:Kanaya Naoaki
    公开号:US20060128685A1
    公开(公告)日:2006-06-15
    The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.
    本发明旨在提供一种强的血小板聚集抑制剂,其不抑制COX-1或COX-2。本发明提供了由式(I)或式(II)表示的化合物,化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂,其中包含任何一种化合物、盐或溶剂。
  • Five-membered heterocyclic derivative
    申请人:Okayama Toru
    公开号:US20060189591A1
    公开(公告)日:2006-08-24
    The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.
    本发明涉及一种由公式(I)表示的化合物:该化合物的盐,或该化合物或盐的溶剂化物;含有任何该化合物、盐和溶剂化物的药物;含有任何该化合物、盐和溶剂化物的缺血性疾病的预防和/或治疗剂;以及含有任何该化合物、盐和溶剂化物的血小板凝集抑制剂。本发明的化合物在不抑制COX-1或COX-2的情况下作为强效的血小板凝集抑制剂非常有用。
查看更多